Abstracts tagged "Janus kinase (JAK) and drug interactions"

Abstract Number: 1459 • ACR/ARHP Annual Meeting 2017
Lack of Drug-Drug Interaction between Filgotinib, a JAK-1 Selective Inhibitor, and a Representative Hormonal Contraceptive Medication, Levonorgestrel/Ethinyl Estradiol
Rebecca Begley¹, Kacey Anderson², Timothy R. Watkins¹, Jing Shen¹, Hao Zheng¹, Eugene Vass¹, Ann Qin², Brian P. Kearney² and Yan Xin², ¹Gilead Sciences, Inc., Foster City, CA, ²Clinical Pharmacology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib is a potent and selective JAK1 inhibitor in clinical development for treatment of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel diseases. Filgotinib…
Abstract Number: 1481 • ACR/ARHP Annual Meeting 2014
Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions
Namour Florence¹, Desrivot Julie¹, Annegret Van der Aa², Chantal Tasset³ and Gerben van 't Klooster², ¹Galapagos, Romainville, France, ²Galapagos NV, Mechelen, Belgium, ³Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium
Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine improved safety and clinical efficacy profiles with a rapid onset of…